Search Tools & Resources

  • YouthBuild Department of Labor Employment and Training Administration

    Rated 0 out of 5
    $700,000.00

    rvices that support education, occupational skills training, and employment services to opportunity youth, ages 16 to 24, while performing meaningful work and service to their communities. The YouthBuild program model prepares participants for quality jobs in a variety of careers, including infrastructure, and contains wrap-around services such as mentoring, trauma-informed care, personal counseling, and employment – all key strategies for addressing community violence. YouthBuild applicants must include construction skills training and may include occupational skills training in other in-demand industries. This expansion into additional indemand industries is the Construction Plus component, a priority in this grant competition. 

  • Minor Use Minor Species Development of Drugs (R01) Department of Health and Human Services Food and Drug Administration

    Rated 0 out of 5
    $500,000.00
    This Notice of Funding Opportunity (NOFO) is issued by the Food and Drug Administration (FDA), Center for Veterinary Medicine (CVM), and solicits Research Project (R01) grant applications from institutions or organizations that propose to develop or support the development of designated new animal drugs intended for minor uses in major species or for use in minor species (MUMS).

    The FDA is authorized to provide grants to assist in defraying the costs of qualified safety and effectiveness testing that could be used to satisfy the requirements for FDA approval of MUMS-designated drugs.

    Only entities developing drugs for veterinary use or parties working as research partners with such entities are eligible for grants.

    • The organization (or applicant) seeking approval of the new animal drug under investigation must have opened an Investigational New Animal Drug (INAD) file with FDA/CVM and must hold a minor use or minor species “designation” granted by FDA/CVM’s Office of Minor Use and Minor Species Animal Drug Development (OMUMS) for that drug for a specified intended use, in accordance with the provisions of section 573 of the Food, Drug and Cosmetic Act (21 U.S.C. 360ccc-2) and 21 CFR part 516.
    • FDA/CVM’s Office of New Animal Drug Evaluation (ONADE) must have reviewed and concurred with the proposed study protocol before an applicant can submit a grant application.